Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00350545
Status:
COMPLETED
Last Update Posted:
2017-11-20
First Post:
2006-07-05
Brief Title:
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The addition of rituximab to prednisone for the initial treatment of chronic GVHD will increase the overall response rate enable a more rapid and effective steroid taper
Detailed Description:
To determine the efficacy of Rituximab as first line of treatment of chronic GVHD Efficacy will be defined as he ability to taper prednisone to a dose of 025 mgkg per day by 6 months without clinical or GVHD relapse recurrence
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2011-00450 | OTHER | National Cancer Institute NCI | None |
| 96950 | OTHER | None | None |
| BMT177 | OTHER | None | None |